Molecular Pancreatic Cancer Program of the University Medical Center Göttingen (MolPAC)
Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology
Modern management of malignant diseases of the pancreas requires coordination of complex diagnostic and therapeutic approaches from various highly specialized physicians and therapists. For this reason we at the University Medical Center Göttingen treat our patients with pancreatic carcinoma within the framework of a pancreatic carcinoma center certified by the German Cancer Aid. This program brings together experts from various medical disciplines and support institutions with the aim of providing our patients with optimal care. This also includes treatment within the framework of clinical studies.
We have learned that pancreatic cancer can differ significantly from each other even if they originate from the same organ. These differences, which are reflected in different prognoses or responses to chemotherapy, are often caused by specific mutations in the genetic information of tumor cells. In order to be able to treat these mutations specifically, we offer our patients a molecular characterization of the tumor tissue with the aim of identifying potentially therapeutically useful genetic alterations within the framework of our molecular pancreas program. If therapeutically useful gene alterations can be detected during molecular characterization, these can be used after failure of the therapy proposed in accepted guidelines.
HiGHmed consortium
The results of the molecular characterization of pancreatic cancer tissue will be discussed with experts from various university hospitals and corresponding recommendations in the G-CCC Molecular Tumor Board and/or the HiGHmed Consortium's cross-site tumor board. At the end of this process we will provide suggestions either for treatment in clinical trials or for study analogous molecular-intensive treatment.
A high degree of IT networking is required in order to carry out the molecular characterization in a meaningful way and to combine it with the clinical characteristics of the respective patients. For this reason, patients with pancreatic carcinomas are specifically investigated at the UMG as part of a joint project funded by the Federal Ministry of Education and Research in cooperation with other German university hospitals. The aim of the research project is to improve the medical care of patients with these difficult to treat tumors by optimal digital networking of different university clinics and research institutions (HiGHmed consortium).
Our Research
In addition to medical care and clinical research in pancreatic cancer, the UMG's Molecular Pancreas Program (MolPAC) provides valuable support for basic research and translational research projects so that we can continue to offer our patients innovative therapy and treatment concepts in the future.
If you yourself are affected, a relative or a heath care professional who treat patients with pancreatic cancer and have questions about our Molecular Pancreas Program, please do not hesitate to contact us via our office for Gastrointestinal Tumor Diseases
Contact
Primarily responsible Physicians/Researchers
Head of the Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology
Prof. Dr. med. Volker Ellenrieder
telephone: +49 551 3962301
e-mail address: volker.ellenrieder(at)med.uni-goettingen.de
PD Dr. med. Alexander König
Head Field Oncology
telephone: +49 551 3963879
fax: +49 551 3966921
e-mail address: christa.lichte-adelski(at)med.uni-goettingen.de
PD Dr. med. Elisabeth Heßmann
Working Group Leader
telephone: +49 551 398902
e-mail address: elisabeth.hessmann(at)med.uni-goettingen.de
